We are live on ! Find out more
VINC

Vincerx Pharma, Inc. Common Stock
VINC

Delisted

VINC was delisted on the 22nd of April, 2025.

Back to rankings

40 hedge funds and large institutions have $42.8M invested in Vincerx Pharma, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 6 increasing their positions, 13 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

268% more capital invested

Capital invested by funds: $11.7M → $42.8M (+$31.2M)

180% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 5

25% more funds holding

Funds holding: 32 → 40 (+8)

54% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 13

Holders
40
Holders Change
+8
Holders Change %
+25%
% of All Funds
0.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
6
Reduced
13
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
+$3.16M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.93M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$485K
4
EP
Eversept Partners
New York
+$251K
5
Marshall Wace
Marshall Wace
United Kingdom
+$226K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$3.41M
2
LFCM
Long Focus Capital Management
Puerto Rico
-$1.3M
3
Bank of America
Bank of America
North Carolina
-$1.21M
4
RCMNY
Rubric Capital Management (New York)
New York
-$750K
5
TC
Tejara Capital
United Kingdom
-$275K
Name Holding Trade Value Shares
Change 		Change in
Stake
LPL Financial
26
LPL Financial
California
$69.7K +$43.5K +689 New
American Century Companies
27
American Century Companies
Missouri
$59.7K +$37.2K +589 New
HCM
28
Hollencrest Capital Management
California
$50.6K – – –
LP
29
LMR Partners
United Kingdom
$50.6K – – –
CAM
30
Cresset Asset Management
Illinois
$50.6K +$31.6K +500 New
LC
31
Lindbrook Capital
California
$38K +$23.7K +375 New
Acadian Asset Management
32
Acadian Asset Management
Massachusetts
$26K -$116K -1,829 -87%
TRCT
33
Tower Research Capital (TRC)
New York
$23K -$2.53K -40 -15%
UBS Group
34
UBS Group
Switzerland
$12.6K -$1.39K -22 -15%
Qube Research & Technologies (QRT)
35
Qube Research & Technologies (QRT)
United Kingdom
$12.5K +$7.84K +124 New
Focus Partners Wealth
36
Focus Partners Wealth
Massachusetts
$10K +$34.4K +545 New
IGWM
37
ICA Group Wealth Management
Colorado
$1.52K +$948 +15 New
Wells Fargo
38
Wells Fargo
California
$810 +$63 +1 +14%
Barclays
39
Barclays
United Kingdom
$116 – – –
Macquarie Group
40
Macquarie Group
Australia
$1 +$822 +13 New
LFCM
41
Long Focus Capital Management
Puerto Rico
– -$1.3M -54,938 Closed
TC
42
Tejara Capital
United Kingdom
– -$275K -11,667 Closed
Walleye Capital
43
Walleye Capital
New York
– -$136K -5,752 Closed
SSA
44
Schonfeld Strategic Advisors
New York
– -$135K -5,700 Closed
MG
45
Marex Group
– -$58.3K -2,470 Closed
Fidelity Investments
46
Fidelity Investments
Massachusetts
– -$7 – –
1
2

VINC Hedge Fund Activity: Q1 2024 in Review

40 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q1 2024, worth a combined $42.8M — up 268% from $11.7M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new VINC positions and 5 closed out — a net gain of 9 holders — while 6 added to existing stakes and 13 trimmed.

The largest buyer was Octagon Capital Advisors, opening a new position worth an estimated $3.16M. The largest seller was Goldman Sachs, cutting an estimated $3.41M.

  • 40 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q1 2024, up from 32 in Q4 2023.
  • Funds reported $42.8M of Vincerx Pharma, Inc. Common Stock stock for Q1 2024, up 268% quarter-over-quarter.
  • 14 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q1 2024 and 5 closed out, a net change of +9 holders.
  • The largest Vincerx Pharma, Inc. Common Stock buyer in Q1 2024 was Octagon Capital Advisors, an estimated $3.16M added.
  • The largest Vincerx Pharma, Inc. Common Stock seller in Q1 2024 was Goldman Sachs, an estimated $3.41M sold.

Based on aggregated 13F filings for Q1 2024.